ClinicalTrials.gg
Active, not recruitingNCT07136805Updated Aug 24, 2026

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

A Phase 3 interventional study of VVN461 Ophthalmic Solution 1.0% and 1.0% prednisolone acetate in Non-infectious Anterior Uveitis, sponsored by VivaVision Biotech, Inc. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by VivaVision Biotech, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China

02

Conditions studied

  • Non-infectious Anterior Uveitis

Browse trials for

03

In context

Uveitis, Anterior

56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.

This study's enrollment of 154 is above the median of 50 across 45 interventional studies indexed under Uveitis, Anterior.

Browse Uveitis, Anterior studies →

Lead sponsor

VivaVision Biotech, Inc is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of signing the form (ICF), the subject must be aged 18 to 70 years (inclusive);
  • At screening, the affected eye is diagnosed with non-infectious anterior uveitis (acute or recurrent acute, only unilateral eye affected patients are included);
  • At screening, the ACC grade of the affected eye is 2+ or 3+ [SUN criteria];
  • At screening, the ACF grade of the affected eye is ≥1 [SUN criteria];

Exclusion criteria

Exclusion Criteria:

  • At screening, the affected eye has an ACC grade of 4+ or hypopyon
  • Diagnosis of intermediate uveitis, posterior uveitis, or panuveitis in either eye at the time of screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    VVN461, 1.0%

    VVN461 Ophthalmic Solution, 1.0%

    Drug: VVN461 Ophthalmic Solution 1.0%

  • Active comparator
    1.0% prednisolone acetate

    1.0% prednisolone acetate, Pred Forte

    Drug: 1.0% prednisolone acetate

Interventions

  • 1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days

  • 1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days

06

What researchers measure

Primary outcomes

  1. Change from baseline in anterior chamber cell (ACC) grade in the study eye at Day 14

    Time frame: Day 14

Secondary outcomes

  1. The proportion of subjects with ACC grade of 0 in the study eye at Day 14

    Time frame: Day 14

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Aug 22, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 30, 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136805
Lead sponsor
VivaVision Biotech, Inc
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Nov 25, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Aug 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VVN461

Start the discussion